Welcome to our dedicated page for aTyr Pharma news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on aTyr Pharma stock.
This page aggregates historical and ongoing news coverage related to the ticker symbol LIFE, which historically represented aTyr Pharma, Inc. on the Nasdaq Capital Market. aTyr describes itself as a clinical stage biotechnology company developing first-in-class medicines from a proprietary tRNA synthetase platform, with a focus on fibrosis and inflammation. Company news has highlighted scientific progress, clinical milestones, and corporate developments tied to this strategy.
Readers can expect news items covering aTyr’s lead therapeutic candidate, efzofitimod, a biologic immunomodulator in clinical development for interstitial lung disease. Press releases have described key events such as Phase 3 EFZO-FIT™ trial updates in pulmonary sarcoidosis, Phase 2 EFZO-CONNECT™ enrollment in systemic sclerosis-related interstitial lung disease, and independent data and safety monitoring board reviews recommending continuation of the EFZO-FIT™ study without modification. Scientific conference presentations, including posters detailing efzofitimod’s mechanism of action through neuropilin-2 and its effects on myeloid cells, also feature prominently.
In addition to clinical and scientific updates, the news stream includes corporate communications such as quarterly results, pipeline summaries, and the announcement of the Nasdaq ticker change from LIFE to ATYR. These releases provide context on how aTyr is advancing its tRNA synthetase-based discovery platform, managing its clinical portfolio, and communicating with the investment community.
For investors, researchers, and clinicians following aTyr, the LIFE news archive offers a structured view of how the company’s programs have evolved over time. By reviewing these items, users can trace the development of efzofitimod in interstitial lung disease, observe the company’s engagement with scientific and investor conferences, and understand the rationale behind the transition from the LIFE ticker to ATYR. Bookmark this page to access a consolidated history of company announcements associated with the LIFE symbol.
aTyr Pharma reported positive results from the Phase 1b/2a clinical trial of ATYR1923 for pulmonary sarcoidosis, providing proof-of-concept for its tRNA synthetase biology platform. The registrational trial is expected to begin in 2022. The company raised $80 million in a common stock offering in September 2021. Q3 2021 results showed cash reserves of $116.4 million, with R&D expenses at $5.1 million. No serious adverse events were reported in the study, and improvements in lung function and symptom measures were observed.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced preclinical findings for ATYR2810 at the SITC Annual Meeting, showcasing its potential to affect tumor-associated macrophages (TAMs) in cancer treatment. The study indicates that ATYR2810, an anti-NRP2 monoclonal antibody, may reduce the suppressive ability of TAMs against T cells and lower ZEB1 gene expression, linked to tumor progression. These insights underscore the drug's potential as a therapy for aggressive cancers, with a Phase 1 study planned for next year.
aTyr Pharma, Inc. (Nasdaq: LIFE) has announced that it will report its third quarter 2021 financial results and provide a corporate update after market close on November 10, 2021. A conference call and webcast will be held the same day at 5:00 pm EST to discuss the results and operational updates. aTyr focuses on developing innovative medicines based on tRNA synthetases and is primarily advancing ATYR1923, which targets Neuropilin-2 to manage inflammatory lung diseases. For further details, visit aTyr's website.
On October 11, 2021, aTyr Pharma (Nasdaq: LIFE) announced that its CEO, Sanjay S. Shukla, will participate in a fireside chat during the Piper Sandler Virtual Investor Day on October 15, 2021, at 9:00 AM ET. The event focuses on developing therapeutics for lung indications and will be moderated by Ted Tenthoff, a Senior Research Analyst at Piper Sandler. A replay of the discussion will be available on aTyr's investor website for 90 days following the event. aTyr Pharma specializes in innovative medicines based on tRNA synthetases for inflammatory lung diseases.
aTyr Pharma (Nasdaq: LIFE) announced the appointment of Robert W. Ashworth, Ph.D., as Vice President of Regulatory Affairs. Dr. Ashworth brings over 35 years of experience, having contributed to the FDA approval of more than 12 new drugs. He will oversee regulatory strategies for aTyr's pipeline, including the advancement of ATYR1923 for pulmonary sarcoidosis and ATYR2810 for cancer trials expected next year. A stock option grant of 70,000 shares with an exercise price of $8.73 was also awarded to him, effective October 4, 2021.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced it will present a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 10-14, 2021. The poster, titled ATYR2810, an anti-NRP2 monoclonal antibody, targets tumor associated macrophages, will showcase the therapeutic potential of ATYR2810, designed to block the interaction between NRP2 and VEGF in specific aggressive tumors. This investigational drug is currently in IND-enabling studies and represents a significant milestone in aTyr’s innovative research on monoclonal antibodies.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced the closing of a public offering of 10,781,250 shares at $8.00 each, raising gross proceeds of $86.3 million. This includes the full exercise of the underwriters’ option to purchase additional shares. The offering was managed by Piper Sandler and RBC Capital Markets, among others. The funds raised will support aTyr's ongoing research and development efforts, particularly in innovative medicines involving tRNA synthetases. The press release clarifies that this announcement does not constitute an offer to sell securities.
aTyr Pharma, a biotherapeutics company focused on innovative medicines, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, scheduled for September 20-23, 2021. The presentation, led by President and CEO Sanjay S. Shukla, is set for September 22, 2021, at 3:45 p.m. ET. Attendees will also have the opportunity to engage in virtual one-on-one meetings with management. A replay will be accessible on the company's website post-event.
aTyr Pharma, a clinical-stage biotherapeutics company, announced the pricing of its underwritten public offering of 9,375,000 shares at $8.00 per share, aiming for gross proceeds of approximately $75 million. The offering includes a 30-day option for underwriters to purchase an additional 1,406,250 shares. The deal is expected to close by September 20, 2021, subject to customary conditions. Piper Sandler and RBC Capital Markets are the joint book-running managers, while Laidlaw & Company and Roth Capital Partners serve in advisory roles.
aTyr Pharma, Inc. (Nasdaq: LIFE) has announced an underwritten public offering of its common stock, with underwriters being granted a 30-day option to purchase additional shares. This offering is subject to market conditions and there is no assurance of completion or specific terms. The offering is made under a shelf registration statement declared effective on August 23, 2021. Piper Sandler and RBC Capital Markets are the joint book-running managers for the offering. A final prospectus supplement will provide more details.
FAQ
What is the current stock price of aTyr Pharma (LIFE)?
What is the market cap of aTyr Pharma (LIFE)?
